$385.7 M

SEEL Mkt cap, 11-May-2021
Seelos Therapeutics Net income (Q1, 2021)-19.1 M
Seelos Therapeutics EBIT (Q1, 2021)-16.6 M
Seelos Therapeutics Cash, 31-Mar-202138.7 M
Seelos Therapeutics EV352.6 M

Seelos Therapeutics Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

1.6m799.4k781.5k119.6k5.2m1.2m28.0k5.5m1.9m475.0k462.0k1.3m626.0k464.0k4.3m375.0k

Cost of goods sold

1.0m115.2k76.4k83.8k119.2k702.0k15.0k75.0k485.0k233.0k509.0k142.0k233.0k93.0k111.0k

Gross profit

588.9k684.3k705.1k35.8k5.0m490.0k13.0k5.4m1.4m242.0k(47.0k)1.1m393.0k371.0k4.2m

Gross profit Margin, %

37%86%90%30%98%41%46%99%74%51%(10%)89%63%80%97%

R&D expense

2.0m621.3k1.4m1.2m2.2m1.5m919.0k1.4m2.1m1.9m3.3m3.1m4.6m2.8m2.8m409.0k412.0k839.0k2.0m217.0k162.0k769.0k9.0m1.7m2.6m3.7m1.4m14.1m

General and administrative expense

3.7m2.3m4.0m3.7m4.4m3.8m2.9m3.1m2.9m2.7m3.1m2.7m2.4m2.4m2.3m1.8m1.4m1.6m1.8m2.1m2.1m1.9m3.3m1.7m1.4m1.8m1.9m2.5m

Operating expense total

8.4m2.9m5.4m4.9m6.5m4.5m3.2m3.5m4.1m4.6m6.4m5.8m7.0m5.2m5.1m2.2m1.9m2.4m3.7m2.4m2.2m2.7m12.3m3.4m4.1m5.5m3.3m16.6m

EBIT

(7.8m)(2.2m)(4.7m)(4.9m)(3.1m)(4.1m)(3.2m)(3.5m)1.2m(3.2m)(6.1m)(5.8m)(5.9m)(4.8m)(4.7m)(1.4m)(1.9m)(2.4m)(3.7m)(2.4m)(2.2m)(2.7m)(12.3m)(3.4m)(3.7m)(5.5m)(3.3m)(16.6m)

EBIT margin, %

(491%)(279%)(596%)(4060%)(60%)(340%)(11296%)23%(168%)(1289%)(1260%)(463%)(769%)(1015%)(32%)(982%)

Interest expense

75.7k105.5k173.5k168.4k123.9k213.0k174.0k107.0k69.0k44.0k146.0k157.0k254.0k279.0k258.0k251.0k95.0k3.0k3.0k16.0k11.0k1.0k4.0k3.0k990.0k

Interest income

3.5k2.1k

Pre tax profit

(2.9m)

Income tax expense

(362.3k)4.0k2.0k1.0k

Net Income

(7.8m)(2.2m)(4.7m)(4.9m)(2.5m)(3.9m)(3.0m)(3.3m)1.9m(3.1m)(6.4m)(5.2m)(5.0m)(2.5m)(3.3m)(1.3m)8.1m(1.5m)(3.8m)(2.3m)(2.3m)(2.8m)(35.5m)(1.9m)(3.2m)(4.8m)(3.7m)(19.1m)

Seelos Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

9.1m8.9m21.5m17.9m16.9m24.8m20.6m22.5m17.4m16.1m16.2m7.4m5.8m6.9m2.7m5.6m3.8m7.8m8.5m5.7m6.8m5.3m11.3m9.7m15.3m12.7m5.9m38.7m

Accounts Receivable

44.9k106.7k891.9k460.6k3.8m681.0k35.0k69.0k49.0k829.0k513.0k664.0k575.0k688.0k687.0k398.0k

Prepaid Expenses

106.7k200.7k350.9k865.3k1.5m232.0k338.0k235.0k605.0k730.0k869.0k1.0m1.4m939.0k737.0k424.0k181.0k322.0k216.0k240.0k294.0k198.0k1.0m527.0k896.0k1.5m1.9m2.6m

Inventories

303.1k427.3k450.1k275.0k338.0k364.0k377.0k321.0k217.0k411.0k142.0k405.0k778.0k800.0k

Current Assets

9.4m9.3m23.1m19.7m26.7m26.3m21.7m23.5m18.8m18.4m18.0m9.8m8.2m9.1m4.9m7.2m5.1m8.6m8.7m5.9m7.1m5.5m12.3m10.3m16.2m14.2m7.8m41.3m

PP&E

4.5m4.4m4.3m4.2m198.5k566.0k549.0k1.4m1.3m1.3m1.4m1.4m1.3m1.2m1.2m1.1m142.0k121.0k100.0k66.0k56.0k46.0k

Goodwill

1.1m1.1m8.8m

Total Assets

14.1m14.0m31.9m29.2m40.7m26.9m22.3m25.0m20.3m19.8m19.6m11.4m9.6m10.4m6.2m8.4m5.4m8.8m8.8m6.0m7.2m5.6m12.3m10.3m16.2m14.2m7.8m41.4m

Accounts Payable

2.2m1.5m737.5k694.8k2.0m1.5m615.0k992.0k1.1m1.2m880.0k446.0k417.0k1.1m1.6m1.4m485.0k140.0k262.0k344.0k1.1m322.0k2.4m1.0m1.8m3.3m630.0k1.6m

Short-term debt

4.0m4.0m4.0m4.0m1.4m2.7m1.2m1.2m531.0k919.0k2.7m8.7m8.1m7.4m2.3m

Current Liabilities

3.7m2.9m9.9m10.9m14.8m11.0m8.4m14.6m7.0m6.4m7.2m5.0m6.9m13.2m13.3m12.6m2.6m1.8m1.8m1.7m1.9m1.4m5.5m7.2m3.7m13.3m

Long-term debt

4.0m4.0m2.8m1.1m4.3m4.0m7.2m3.2m

Total Debt

4.0m4.0m4.0m4.0m4.0m6.8m2.5m2.7m1.2m1.2m4.8m4.9m9.9m8.7m8.1m7.4m5.5m

Total Liabilities

8.5m7.7m11.7m12.4m17.2m13.5m10.4m7.8m18.0m14.6m17.5m17.3m15.6m15.9m4.5m2.2m2.5m1.7m1.9m1.5m9.3m5.3m5.9m7.4m4.1m16.6m

Common Stock

20.0k20.7k26.6k27.0k29.6k37.0k38.0k38.0k38.0k40.0k50.0k50.0k50.0k62.0k62.0k8.0k8.0k13.0k15.0k16.0k23.0k28.0k20.0k21.0k27.0k44.0k44.0k78.0k

Preferred Stock

Additional Paid-in Capital

218.0m220.9m244.2m245.8m255.0m277.1m278.6m280.2m281.3m284.5m297.9m298.2m298.6m304.5m305.2m308.5m309.1m316.3m319.8m322.5m325.8m327.5m43.3m47.1m55.7m67.6m68.3m119.0m

Retained Earnings

(212.4m)(214.7m)(224.1m)(229.0m)(231.5m)(263.7m)(266.7m)(271.3m)(269.5m)(272.6m)(296.3m)(301.5m)(306.5m)(311.4m)(314.7m)(316.0m)(308.2m)(309.7m)(313.5m)(318.3m)(320.5m)(323.4m)(40.3m)(42.2m)(45.4m)(60.9m)(64.6m)(94.3m)

Total Equity

5.6m6.3m20.2m16.8m23.5m13.4m11.9m8.9m11.8m12.0m1.7m(3.2m)(7.9m)(6.8m)(9.4m)(7.5m)842.0k6.6m6.3m4.3m5.3m4.1m3.0m4.9m10.3m6.8m3.7m24.8m

Financial Leverage

2.5 x2.2 x1.6 x1.7 x1.7 x2 x1.9 x2.8 x1.7 x1.7 x11.8 x-3.5 x-1.2 x-1.5 x-0.7 x-1.1 x6.4 x1.3 x1.4 x1.4 x1.4 x1.4 x4.1 x2.1 x1.6 x2.1 x2.1 x1.7 x

Seelos Therapeutics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(11.2m)(13.4m)(4.7m)(9.6m)(12.1m)(12.6m)(15.6m)(3.3m)(1.4m)(4.5m)(6.4m)(11.7m)(16.7m)(2.5m)(5.8m)(7.1m)8.1m2.8m(2.3m)(4.5m)(7.4m)(35.5m)(37.4m)(40.6m)(4.8m)(8.6m)(19.1m)

Depreciation and Amortization

417.5k509.3k144.2k300.4k509.9k41.0k57.0k20.0k40.0k102.0k74.0k149.0k224.0k73.0k145.0k217.0k56.0k77.0k98.0k13.0k23.0k33.0k

Accounts Receivable

44.7k(17.2k)(564.9k)(133.7k)(2.2m)(370.0k)276.0k(10.0k)10.0k(770.0k)165.0k14.0k103.0k(169.0k)(168.0k)121.0k

Inventories

(167.0k)(291.2k)(298.3k)(249.0k)(338.0k)(28.0k)(41.0k)15.0k58.0k(136.0k)133.0k64.0k(73.0k)(140.0k)

Accounts Payable

1.6m942.6k(400.1k)(442.7k)377.0k(656.0k)(1.5m)67.0k202.0k295.0k(68.0k)(442.0k)(443.0k)(374.0k)133.0k(225.0k)(202.0k)(547.0k)(425.0k)286.0k996.0k264.0k201.0k(1.2m)(371.0k)2.5m(166.0k)(259.0k)

Cash From Operating Activities

(4.5m)(7.3m)(5.2m)(8.7m)(11.6m)(11.7m)(16.1m)(192.0k)(4.8m)(8.9m)(6.1m)(14.7m)(21.3m)(6.1m)(9.5m)(10.4m)(1.2m)(4.9m)(8.1m)(1.9m)(3.9m)(6.5m)(7.9m)(11.3m)(14.2m)(6.4m)(13.4m)(11.3m)

Purchases of PP&E

(176.7k)(198.5k)(20.0k)(20.0k)(23.1k)(116.0k)(119.0k)(355.0k)(432.0k)(500.0k)(165.0k)(188.0k)(216.0k)(6.0k)(18.0k)(18.0k)

Cash From Investing Activities

357.6k(198.5k)(280.0k)(278.0k)1.4m3.5m3.5m(305.0k)(382.0k)(450.0k)(165.0k)(188.0k)(216.0k)(6.0k)262.0k262.0k

Short-term Borrowings

401.0k(401.0k)(755.0k)(1.5m)(2.3m)(7.1m)(7.1m)(7.1m)(5.2m)

Long-term Borrowings

(15.2k)(15.2k)(1.0k)(1.9k)(3.2k)(8.0k)(17.0k)(25.0k)(3.0k)(5.0k)(1.0k)(3.0k)(5.0k)

Cash From Financing Activities

4.1m7.2m19.5m19.5m19.5m16.7m16.7m1.6m542.0k3.4m11.0m11.0m16.0m9.1m8.1m11.8m(7.1m)(1.1m)2.4m1.3m4.4m5.4m19.2m21.0m29.5m8.9m9.0m34.3m

Net Change in Cash

(5.5k)(267.8k)14.1m10.5m9.4m9.6m5.5m1.1m(4.0m)(5.3m)4.8m(4.0m)(5.6m)3.0m(1.2m)1.7m1.7m5.7m6.4m(653.0k)505.0k(1.0m)11.3m9.7m15.3m2.4m(4.4m)23.0m

Interest Paid

174.4k174.4k74.3k148.2k222.6k125.0k189.0k354.0k508.0k92.0k92.0k92.0k11.0k16.0k4.0k8.0k4.0k

Income Taxes Paid

Seelos Therapeutics Ratios

USDQ2, 2011

Financial Leverage

2.5 x